Krka has set up an “independent organisational unit” dedicated to biosimilars as part of its stated intention to “embark on the area of similar biological medicines”. Noting that a separate unit had been set up “due to the scale and complexity of content in this field”, the Slovenian firm said it would place a “priority focus on treatments for autoimmune diseases and diabetes”.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?